US status

Compoundable

By Peptide America · Publisher · Reviewed September 2026

Section 503A lets a licensed pharmacy compound a drug for an individual patient with a valid prescription, drawing on bulk substances the FDA has nominated for its interim list. Category 1 of that list holds substances under review without identified safety concerns; pharmacies may compound them while the review continues.

Category 1 is a permission during review, not an approval, and it can end. The molecules below hold that position today, each verified on the date shown; sermorelin adds a stronger foundation, since it was itself an approved drug withdrawn for commercial rather than safety reasons.

Molecules holding this status

Molecule	Class	US status	Position
SermorelinGHRH(1–29); formerly Geref	GH secretagogues	Compoundable (503A)	Previously approved (Geref), discontinued in 2008 for business reasons; compounded today under 503A. Verified August 2026.
NAD+Nicotinamide adenine dinucleotide	Mitochondrial	Compoundable (503A)	Category 1 of the interim 503A bulks list; compoundable with a valid prescription while FDA evaluates. Verified August 2026.
Glutathione	Mitochondrial	Compoundable (503A)	Category 1 of the interim 503A bulks list; compoundable with a valid prescription. Verified August 2026.
GHK-CuCopper tripeptide-1	Repair peptides	Compoundable (503A)	Nominations withdrawn April 2026; the non-injectable route was restored to Category 1 in May, the injectable route was not and has no lawful route. Verified August 2026.
Vasoactive intestinal peptideVIP; aviptadil	Gut peptides	Compoundable (503A)	Category 1 of the interim 503A bulks list; a pharmacy may compound it while FDA review continues. No approved product containing it exists.

SermorelinCompoundable (503A)
GHRH(1–29); formerly Geref
Previously approved (Geref), discontinued in 2008 for business reasons; compounded today under 503A. Verified August 2026.
NAD+Compoundable (503A)
Nicotinamide adenine dinucleotide
Category 1 of the interim 503A bulks list; compoundable with a valid prescription while FDA evaluates. Verified August 2026.
GlutathioneCompoundable (503A)
Category 1 of the interim 503A bulks list; compoundable with a valid prescription. Verified August 2026.
GHK-CuCompoundable (503A)
Copper tripeptide-1
Nominations withdrawn April 2026; the non-injectable route was restored to Category 1 in May, the injectable route was not and has no lawful route. Verified August 2026.
Vasoactive intestinal peptideCompoundable (503A)
VIP; aviptadil
Category 1 of the interim 503A bulks list; a pharmacy may compound it while FDA review continues. No approved product containing it exists.

The pending page tracks six peptides that a July 2026 advisory vote recommended adding to this list; none has crossed yet.

Elsewhere in this index

Evidence reviews

CJC-1295 With Ipamorelin: The EvidenceWhat is known about CJC-1295 taken with ipamorelin?
Sermorelin vs Tesamorelin: How They DifferHow do sermorelin and tesamorelin differ?
Sermorelin: The Trial Record Stopped in 2005Does sermorelin produce the effects attributed to growth hormone therapy?
NAD+ Infusions and the Precursor TrialsDo the nicotinamide riboside and nicotinamide mononucleotide trials support intravenous NAD+?
Glutathione Injections for Skin LighteningIs injectable glutathione established for skin lightening, and what has the FDA said about it?
GLOW and KLOW Peptide Blends: What Is in ThemWhat are the GLOW and KLOW peptide blends, and has either been tested in people?
GHK-Cu: Topical Evidence, Injectable SalesDoes the cosmetic-science evidence for copper tripeptide support injecting it?
Aviptadil for COVID-19: Trial ResultsDid aviptadil improve outcomes in severe COVID-19?
A Lawful Peptide Is Not a Proven OneDoes a lawful compounding status mean a peptide is supported by evidence?

Reference tables

The 2026 recordWhat happened to United States peptide compounding law in 2026, in order?
The nomination trackerWhat became of each peptide's nomination to the 503A bulks list?
The human trial record, by moleculeHow many human clinical trials exist for each peptide in this index?
The WADA Prohibited ListWhich peptides in this index are prohibited in sport, and under which class?

Definitions

Section 503AThe provision under which a licensed pharmacy compounds a drug for an individual patient with a valid prescription.
The interim 503A bulks listThe FDA's interim list of bulk drug substances nominated for use in 503A compounding, sorted into categories.
Category 1Substances under FDA review without identified safety concerns; pharmacies may compound them while review continues.
Compounded drugA drug prepared by a pharmacy rather than manufactured under an approval. FDA does not approve it or review it for safety, effectiveness, or quality.
All glossary terms